Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼¹ IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients

BOSTON, July 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announc...

Related Keywords

Boston ,Massachusetts ,United States ,United Kingdom ,Great Britain ,Philip Beales ,David Meeker ,University College London ,European Commission ,Drug Administration ,Great Britain Medicines Healthcare Products Regulatory Agency ,Rhythm Pharmaceuticals ,Nasdaq ,Health Technology Assessment ,Rhythm Pharmaceuticals Inc ,European Union ,European Medicines Agency ,Committee For Medicinal Products Human Use ,Institute Of Child Health ,Medicinal Products ,Human Use ,Chief Executive Officer ,Child Health ,Healthcare Products Regulatory Agency ,Rhythm Engine ,